VivoSim data shows superiority in NAM liver toxicity prediction
The presentations at ESTIV 2026 demonstrated >90% sensitivity and <5% false positives for liver and GI toxicity, including for antibody drug conjugates.
See the latest news and media coverage for VivoSim. We track all announcements, press releases, and industry mentions in real time, all in one place.
3D liver and intestine toxicology model provider
vivosim.aiLast updated
In short: VivoSim presented high-accuracy toxicity prediction models, secured a $4 million public offering, and expanded its leadership team.
The presentations at ESTIV 2026 demonstrated >90% sensitivity and <5% false positives for liver and GI toxicity, including for antibody drug conjugates.
The tool integrates NAMkind intestinal tissues with machine learning to achieve 96% predictive accuracy for diarrhea risk.
The offering includes $3 million initial closing and $1 million second closing, with common stock and warrants.
He will lead commercial expansion and secure strategic partnerships for liver and GI toxicity solutions.
Short interest in VivoSim Labs Inc (NASDAQ:VIVS) decreased during the last reporting period, falling from 138.83K to 38.36K. This put 1.49% of the company's publicly...
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE)-- VivoSim Labs, Inc. (Nasdaq: VIVS), (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for...
SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter...
In response, VivoSim Labs requested and attended a hearing before a Nasdaq Hearings Panel on February 27, 2025, where it presented a plan to regain...
Track VivoSim and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to VivoSim and other trending companies.